(S (NP-SBJ (NP (DT The) (NN NF-kappa) (NN B) (NN inhibitor)) (, ,) (NP (NN tepoxalin)) (, ,)) (VP (VBZ suppresses) (NP (NP (NN surface) (NN expression)) (PP (IN of) (NP (DT the) (NN cell) (NN adhesion) (NNS molecules) (NP-COOD (NP (NN CD62E)) (, ,) (NP (NN (CD18 CD11b))) (CC and) (NP (NN CD106))))))) (. .))
(S (NP-SBJ-51 (NP (NN Tepoxalin)) (, ,) (NP (NP (DT a) (JJ dual) (NN enzyme) (NN inhibitor)) (PP (IN of) (NP-COOD (NP (NN cyclooxygenase)) (CC and) (NP (NN 5-lipoxygenase)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (NP-SBJ (-NONE- *-51)) (VP (TO to) (VP (VB inhibit) (NP (NN T-cell) (NN activation)))))))) (. .))
(S (NP-SBJ (PRP$ Its) (JJ immunosuppressive) (NN property)) (VP (VBZ is) (ADJP-PRD (JJ distinct) (PP (IN from) (NP (NN cyclosporin)))) (SBAR (IN because) (S (NP-SBJ-COOD (NP (RB only) (NN tepoxalin)) (, ,) (CONJP (CC but) (RB not)) (NP (NN cyclosporin)) (, ,)) (VP (VBZ suppresses) (NP (NN NF-kappa) (NN B) (NN activation)))))) (. .))
(S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ (NN tepoxalin)) (ADVP (RB selectively)) (VP (VBZ inhibits) (NP (NP (ADJP (NP (JJ intercellular) (NN adhesion) (NN molecule-1) (-LRB- -LRB-) (NN ICAM-1) (, ,) (NN CD54) (-RRB- -RRB-) (NN /MAC-1) (-LRB- -LRB-) (NN (CD18 CD11b)) (-RRB- -RRB-)) (JJ dependent)) (NN adhesion)) (PP (IN of) (NP (JJ polymorphonuclear) (NNS cells))) (PP (TO to) (NP (ADJP (NN IL-1) (JJ activated)) (JJ human) (JJ umbilical) (NN vein) (JJ endothelial) (NNS cells)))))))) (. .))
(S (NP-SBJ (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NN inhibition)))) (VP (VBZ is) (ADJP-PRD (JJ related) (PP (TO to) (NP (NP (DT the) (NN surface) (NN expression)) (PP (IN of) (NP (JJ several) (NN cell) (NN adhesion) (NNS molecules))))))) (. .))
(S (NP-SBJ (NP (NN Flow) (NN cytometry) (NNS analyses)) (PP (IN on) (NP (NP (VBN cultured) (NNS cells)) (SBAR (WHNP-53 (WDT that)) (S (NP-SBJ-54 (-NONE- *T*-53)) (VP (VBD were) (VP-COOD (VP (VBN treated) (NP (-NONE- *-54)) (PP (IN with) (NP-COOD (NP (NN tepoxalin)) (CC or) (NP (NP (JJ antisense) (NNS oligonucleotides)) (PP (TO to) (NP (NP (DT the) (NN (p50 P65)) (NN subunit)) (PP (IN of) (NP (NN NF-kappa) (NN B))))))))) (, ,) (CC and) (RB then) (VP (VBN stimulated) (NP (-NONE- *-54)) (PP (IN with) (NP (NN PMA)))) (, ,)))))))) (VP (VBD revealed) (NP-COOD (NP (NP (DT a) (VBN reduced) (NN expression)) (PP (IN of) (NP-108 (NN (CD18 CD11b)))) (PP-109 (IN on) (NP (JJ monocytic) (NN HL60) (NNS cells)))) (, ,) (CC and) (NP (NP-COOD=108 (NP (NP (JJ endothelial) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NN CD62E)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ vascular) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NN CD106)) (-RRB- -RRB-)))) (PP=109 (IN on) (NP (JJ human) (JJ umbilical) (NN vein) (JJ endothelial) (NNS cells)))))) (. .))
(S (NP-SBJ (NP (NN Expression)) (PP (IN of) (NP (NP (JJ other) (NN adhesion) (NNS molecules)) (PP (JJ such) (IN as) (NP-COOD (NP (NP (NN lymphocyte) (NN function) (NN associated-antigen-1)) (PRN (-LRB- -LRB-) (NP (NN (CD18 CD11a))) (-RRB- -RRB-))) (CC and) (NP (NN CD54))))))) (VP (VBD were) (ADJP-PRD (JJ unaffected))) (. .))
(S (NP-SBJ (NN Tepoxalin)) (ADVP (RB also)) (VP (VBD inhibited) (NP (NP (DT the) (NN secretion)) (PP (IN of) (NP (NP (DT a) (ADJP (NP (NN NF-kappa) (NN B)) (JJ regulated)) (NN chemokine)) (, ,) (NP (NN IL-8)) (, ,) (NP (NP (DT a) (JJ known) (NN inducer)) (PP (IN of) (NP (NN (CD18 CD11b)) (NN expression)))))))) (. .))
(S (ADVP (RB Thus)) (NP-SBJ (NP (DT the) (NN suppression)) (PP (IN of) (NP (NN (CD18 CD11b)) (NN expression))) (PP (IN by) (NP (NN tepoxalin)))) (VP (MD may) (VP (VB involve) (NP (NN IL-8)))) (. .))
(S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR-COOD (SBAR (IN that) (S (PP (IN by) (S-LGS (NP-SBJ (-NONE- *)) (VP (VBG inhibiting) (NP (NN NF-kappa) (NN B) (NN activation))))) (, ,) (NP-SBJ-56 (NP (NN surface) (NN expression)) (PP (IN of) (NP (JJ several) (NN adhesion) (NNS molecules)))) (VP (MD can) (VP (VB be) (VP (VBN modulated) (NP (-NONE- *-56))))))) (CC and) (SBAR (IN that) (S (NP-SBJ (NN tepoxalin)) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ useful)) (PP (IN in) (S (NP-SBJ (-NONE- *)) (VP (VBG treating) (NP (NP (VBN selected) (ADJP (NN adhesion) (JJ mediated)) (NNS events)) (PP (JJ such) (IN as) (NP-COOD (NP (NN leukocyte) (NN migration)) (CC or) (NP (JJ atherosclerotic) (NN plaque) (NN formation)))))))))))))) (. .))
